-
2023-504694-20-00
9
2017-01-13
pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukem
-
2024-512358-78-00
7
2015-01-20
Solid Tumors
-
2025-523997-18-00
9
2026-06-29
Sarcoma
-
2023-510559-41-00
4
2026-06-15
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
-
2024-519246-75-01
4
2026-06-15
Patients With Muscle-Invasive Bladder Cancer
-
2025-521587-35-00
5
2026-06-03
Metastatic colorectal cancer
-
2025-523106-32-00
5
2026-05-25
Obesity or Overweight and Type 2 Diabetes
-
2025-521702-18-00
1
2026-05-21
Locally advanced unresectable or metastatic colorectal cancer (CRC)
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2025-523690-41-00
5
2026-05-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2025-524366-21-00
5
2026-04-29
treatment-naive Chronic Lymphocytic Leukemia
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2025-524542-10-00
4
2026-04-14
Endometrial cancer
-
2025-523263-37-00
10
2026-04-08
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia
-
2024-513750-30-00
4
2026-03-25
Sickle Cell Disease
-
2023-504957-11-00
5
2026-03-24
Metastatic castration resistant prostate cancer
-
2025-523160-20-00
1
2026-03-23
Advanced solid tumors
-
2025-521621-33-00
6
2026-03-16
Melanoma
-
2025-522012-16-00
4
2026-03-13
Breast Cancer
-
2025-522713-29-00
5
2026-03-12
Metastatic Castration-resistant Prostate Cancer (mCRPC)